E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Incidence and Clinical Course of Thrombotic Thrombocytopenic Purpura Due to Ticlopidine Following Coronary Stenting
TL;DR: The findings of a TTP incidence of 0.02% in a cohort of ticlopidine-treated patients following coronary stenting suggests that TTP occurs much more commonly in this population than the estimated incidence of0.0004% in the general population.
Journal ArticleDOI
Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts A Pooled Analysis of Five Randomized Clinical Trials
Marco Roffi,Debabrata Mukherjee,Derek P. Chew,Deepak L. Bhatt,Leslie Cho,Mark Robbins,Khaled M. Ziada,Danielle M. Brennan,Stephen G. Ellis,Eric J. Topol +9 more
TL;DR: Intravenous platelet GP IIb/IIIa receptor inhibition does not improve outcomes after PCI of bypass grafts, and in the absence of mechanical emboli protection, this procedure is associated with high incidence of death and nonfatal ischemic events.
Journal ArticleDOI
Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation.
David R. Holmes,Peter B. Berger,Judith S. Hochman,Christopher B. Granger,Trevor D. Thompson,Robert M. Califf,Alec Vahanian,Eric R. Bates,Eric J. Topol +8 more
TL;DR: The incidence, patient characteristics, timing, clinical course, and angiographic findings differ between the 2 groups, and Mortality from cardiogenic shock is similarly high among patients with and without ST-segment elevation.
Journal ArticleDOI
Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Eric J. Topol,R Bonan,D Jewitt,Ulrich Sigwart,V V Kakkar,M Rothman,D de Bono,Jill Ferguson,J T Willerson,J Strony +9 more
TL;DR: Hirulog was associated with a rapid onset, dose-dependent anticoagulant effect, minimal bleeding complications, and at doses of 1.8-2.2 mg/kg, a rate of 3.9% for abrupt vessel closure.
Journal ArticleDOI
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
Jeffrey Lefkovits,Russell J. Ivanhoe,Robert M. Califf,Bruce A. Bergelson,Keaven M. Anderson,Gail L. Stoner,Harlan F. Weisman,Eric J. Topol +7 more
TL;DR: It is concluded that adjunctive c7E3 therapy during direct and rescue PTCA decreased acute ischemic events and clinical restenosis in the EPIC trial, and initial evidence of benefit for glycoprotein IIb/IIIa receptor blockade during P TCA for acute myocardial infarction is provided.